Skip to main content
Premium Trial:

Request an Annual Quote

Allowing Access

Biopharmaceutical firm AstaZeneca has announced that it is teaming up with researchers at the non-profit Medicines for Malaria Venture in an effort to "identify novel candidate drugs for the treatment of malaria." The MMV team "will screen 500,000 compounds in AstraZeneca's unique library for activity against P. falciparum, the most lethal of malaria parasites," according to the drug company's statement. Vicky Avery of Griffith University in Brisbane, Australia, "will conduct the screening on behalf of MMV. Promising compounds identified through the screening process will be starting points for antimalarial drug discovery projects," and will be tailored to become "suitable candidates for clinical testing," according to AZ. David Brennan, the firm's CEO, says in a statement that "we will only find solutions to today's global health challenges through collaborative efforts," adding that "opening up our compound library to MMV is an important step toward addressing the enormous unmet medical needs of the developing world."

Earlier this month, Forbes' The Science Business blog examined ways in which major drug companies are beginning to "open up" their operations in order to promote scientific progress.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.